FDA Clears QIAGEN's First Bloodstream Infection Panel, Expanding Diagnostic Reach
QGEN sits 35% above its 52-week low of $32.53.
Summary
The FDA cleared QIAGEN's QIAstat-Dx BCID GPF Plus AMR Panel, its first bloodstream infection diagnostic on the platform. This opens a new, high-acuity testing category in the U.S., adding to respiratory, GI, and CNS menus. The panel detects 20 gram-positive and fungal targets plus 10 resistance markers in about an hour, addressing the urgent need for rapid sepsis diagnostics. A complementary gram-negative panel is already under FDA review, signaling a broader bloodstream infection franchise. The news follows strong Q2 earnings and recent private equity takeover interest, reinforcing the commercial momentum of the QIAstat-Dx platform.
At the time of this announcement, QGEN was trading at $43.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.